GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound A [WO2023149450A1] | CTX-177 | CTX177
Compound class:
Synthetic organic
Comment: The chemical structure for ocipumaltib was included in WHO INN proposed list 133 (10th July 2025). It is one of the compounds claimed as MALT1 paracaspase inhibitors in patent WO2023149450A1 [1], making this likely to be the INN for Chordia Therapeutics' clinical lead CTX-177. MALT1 is a therapeutic target for the treatment of lymphomas in which the protein is aberrantly activated.
|
|
References |
1. Ozaki R, Fujikawa R, Ono K, Morishita D, Sato Y, Mizutani A. (2023)
Cancer treatment agent including malt1 inhibiting drug as active ingredient. Patent number: WO2023149450A1. Assignee: Ono Pharmaceutical Co., Ltd., Chordia Therapeutics Co., Ltd.. Priority date: 01/02/2023. Publication date: 10/08/2023. |